Product image of Latanoprost Aurovitas (Latanoprost) supplied by GNH India

Latanoprost Aurovitas

Active Ingredient:
Latanoprost
Origin:
EU

Latanoprost Aurovitas (Latanoprost)

Latanoprost, the active ingredient in Latanoprost Aurovitas, is a prostaglandin analog presented as an ophthalmic eye‑drop solution for ocular administration. It acts to increase uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure in adult patients with open‑angle glaucoma or ocular hypertension.

GNH India supplies Latanoprost Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide for the management of glaucoma and ocular hypertension, under strict quality standards and regulatory compliance.

Manufacturer / TM Owner

Generis Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Latanoprost is a prostaglandin analog used to manage ocular conditions characterized by elevated intra‑ocular pressure.

  • Open‑angle glaucoma: reduces intra‑ocular pressure, helping to prevent optic nerve damage.
  • Ocular hypertension: lowers eye pressure to reduce the risk of progression to glaucoma.
  • Secondary open‑angle glaucoma: provides pressure reduction in cases secondary to other ocular conditions.

How It Works

  • Latanoprost acts as a prostaglandin F2α receptor agonist in the eye, binding to FP receptors on the ciliary muscle and scleral tissue. This activation enhances uveoscleral outflow of aqueous humor, leading to a decrease in intra‑ocular pressure and helping to protect the optic nerve from pressure‑related damage.

Side Effects

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects

  • Eye redness: mild conjunctival hyperemia.
  • Increased eyelash growth: longer, thicker lashes.
  • Iris pigmentation change: gradual darkening of eye colour.
  • Eye irritation: transient burning or stinging sensation.
  • Blurred vision: temporary visual disturbance after instillation.
  • Foreign body sensation: feeling of something in the eye.

Serious or Rare Side Effects

  • Severe eye inflammation: uveitis or iritis requiring medical attention.
  • Allergic reaction: swelling, itching, or rash around the eye.
  • Corneal edema: swelling of the cornea that can affect vision.
  • Macular edema: fluid accumulation in the retina, potentially impairing central vision.
  • Vision loss: sudden decrease in visual acuity.
  • Persistent ocular pain: ongoing discomfort beyond the initial period.

Precautions & Warnings

When prescribing Latanoprost, clinicians should consider several safety measures.

  • Monitor intra‑ocular pressure: measure regularly after initiation.
  • Assess for ocular infections: avoid use if active infection is present.
  • Avoid contact lenses: discontinue lens wear during treatment.
  • Use with caution in patients with a history of uveitis: monitor for inflammation.
  • Pregnancy and lactation: safety not established; weigh benefits against potential risks.
  • Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Avoid Interactions

Latanoprost may interact with other ophthalmic agents, requiring attention to potential additive effects.

Major Interactions (Avoid)

  • Concomitant use of other prostaglandin analogs: may increase risk of ocular side effects.
  • Non‑steroidal anti‑inflammatory eye drops: may reduce Latanoprost efficacy.
  • Systemic carbonic anhydrase inhibitors: additive intra‑ocular pressure‑lowering effect.

Moderate Interactions (Monitor Closely)

  • Beta‑blocker eye drops: combined IOP reduction may require pressure monitoring.
  • Corticosteroid eye drops: may diminish Latanoprost's pressure‑lowering effect.
  • Anticholinergic agents: possible reduced outflow response, monitor IOP.

Frequently Asked Questions

Latanoprost Aurovitas is an ophthalmic eye‑drop formulation containing the prostaglandin analog latanoprost. It is prescribed to lower intra‑ocular pressure in adults with open‑angle glaucoma or ocular hypertension, helping to prevent optic nerve damage and preserve visual function.

Latanoprost acts as an agonist at prostaglandin F2α (FP) receptors in the eye. Activation of these receptors increases uveoscleral outflow of aqueous humor, which reduces intra‑ocular pressure and alleviates the mechanical stress on the optic nerve associated with glaucoma.

The dosing regimen for Latanoprost Aurovitas is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily, but the exact dose and timing should follow the prescriber’s instructions and the patient’s individual response.

Safety data for latanoprost in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To request Latanoprost Aurovitas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to latanoprost is the beta‑blocker class, such as timolol. Latanoprost lowers pressure by increasing outflow, whereas beta‑blockers reduce aqueous humor production. Latanoprost is often preferred for once‑daily dosing and a favorable systemic safety profile, while beta‑blockers may be chosen when prostaglandin‑related side effects are a concern.

Latanoprost eye drops should be stored at room temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from direct light and moisture, and discard any remaining solution after the indicated period after opening, as recommended by the manufacturer.

Latanoprost is applied as a single drop to each affected eye, usually in the evening. The patient should wash hands, avoid touching the tip of the bottle to the eye or any surface, and wait a few minutes before applying other eye medications to prevent dilution or wash‑out.

Serious adverse events, though rare, include severe ocular inflammation such as uveitis or iritis, corneal edema, macular edema, and sudden loss of vision. Any sudden eye pain, redness, or visual changes should prompt immediate medical evaluation.

Latanoprost is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation. It should also be avoided in eyes with active intra‑ocular inflammation, infection, or in patients who have had recent ocular surgery unless specifically advised by an ophthalmologist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Latanoprost

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT